IQVIA Holdings's EBIT per Share for the
three
months ended in Mar. 2026 was $3.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $13.71.
During the past 12 months, the average EBIT per Share Growth Rate of IQVIA Holdings was 8.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 11.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 24.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 13.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for IQVIA Holdings's EBIT per Share or its related term are showing as below:
LTS:0JDM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -10.4 Med: 11.2 Max: 40.2
Current: 11.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of IQVIA Holdings was 40.20% per year. The lowest was -10.40% per year. And the median was 11.20% per year.
LTS:0JDM's 3-Year EBIT Growth Rate is ranked worse than 51.79% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.1
vs LTS:0JDM: 11.20
IQVIA Holdings's EBIT for the
three
months ended in Mar. 2026 was $520 Mil.
IQVIA Holdings (LTS:0JDM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
IQVIA Holdings EBIT per Share Related Terms
IQVIA Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (LTS:0JDM) has a EBIT per Share of $13.71 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on IQVIA Holdings and its competitors. According to the industry distribution chart, IQVIA Holdings ranks #87 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 51.8%.
Is IQVIA Holdings' EBIT per Share too high?
IQVIA Holdings' current EBIT per Share is $13.71. The Medical Diagnostics & Research industry median EBIT per Share is 13.10. IQVIA Holdings' value of $13.71 is 4.7% above this industry median. Based on the distribution chart, IQVIA Holdings ranks #87 out of 168 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IQVIA Holdings has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' EBIT per Share compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #87 out of 168 companies for EBIT per Share. This places IQVIA Holdings in the lower half of its industry. The industry median EBIT per Share is 13.10. IQVIA Holdings' value of $13.71 is 4.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current EBIT per Share of $13.71 is 4.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current EBIT per Share is $13.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Modestly Undervalued. The stock's GF Value™ is $248.52, compared to a current price of $207.24 — trading 16.6% below its estimated fair value. The current EBIT per Share is $13.71 and 4.7% above the Medical Diagnostics & Research industry median of 13.10. IQVIA Holdings' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current EBIT per Share is $13.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $207.24 is trading 16.6% below its estimated GF Value™ of $248.52.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for LTS:0JDM:
EBIT per Share: $13.71
GF Value™: $248.52 vs. price of $207.24 (16.6% below fair value)
Industry Position: 4.7% above the Medical Diagnostics & Research median (#87 of 168)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
87GF Score
Get the complete analysis for LTS:0JDM
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
